Skip to content

To study the mechanism of panax notoginseng in the treatment of aspirin resistance in the secondary prevention of stroke based on TLR4/MyD88/NF-?B signaling pathway

To study the mechanism of panax notoginseng in the treatment of aspirin resistance in the secondary prevention of stroke based on TLR4/MyD88/NF-?B signaling pathway

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045773
Enrollment
Unknown
Registered
2021-04-24
Start date
2022-06-01
Completion date
Unknown
Last updated
2021-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aspirin resistance

Interventions

Sponsors

Xi'an Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 65 Years

Inclusion criteria

Inclusion criteria: 1.Agree to participate in this clinical trial and sign the informed consent; 2.Aged < 65 years, gender unlimited, taking single antiplatelet drug; 3.Essen Stroke Risk Scale score <= 3 points; 4.The traditional Chinese medicine with the effect of promoting blood circulation and removing blood stasis should not be used overlapped in the observation period.

Exclusion criteria

Exclusion criteria: 1.Patients with transient ischemic attack and cerebral infarction requiring double antibody; 2.Patients with cerebral hemorrhage after cerebral infarction, cerebral arteritis, brain tumor, brain trauma, cerebral parasitic disease, rheumatic heart disease; 3.Patients with bleeding tendency or severe bleeding within 3 months; 4.Severe hepatic and renal hematopoiesis and metabolic system diseases; 5.Legal disabled patients (blind, deaf, dumb, intellectual, mental and other physical disabilities caused by other reasons), affecting the evaluation of neurological function defects; 6.Suspected or present a history of alcohol and drug abuse, or other conditions that, in the investigator's judgment, reduce or complicate the likelihood of inclusion; 7.Participating in other clinical trials or participating in clinical trials of other drugs for less than 3 months.

Design outcomes

Primary

MeasureTime frame
Platelet aggregation rate;Thromboxane B2;Toll-like receptor 4;Myeloid differentiation factor 88;ranscription factor;

Secondary

MeasureTime frame
Cyclooxygenase-2;Interleukin-6;C-reactive protein;Thromboxane B2;

Countries

China

Contacts

Public ContactWang Hui

Xi'an Hospital of Traditional Chinese Medicine

18092071903@163.com+86 13572028583

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026